Fever and neutropenia clinical practice guidelines.

Alison G. Freifeld*, Lindsey Robert Baden, Arthur E. Brown, Linda S. Elting, Michael Gelfand, John N. Greene, James I. Ito, Earl King, Guido Marcucci, Jose G. Montoya, Ashley Morris, Gary Noskin, Ken Rolston, Anne F. Schott, Brahm Segal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Significant progress has been made in managing fever and neutropenia in patients with cancer. Although initial empiric antimicrobial treatment remains the foundation of therapy for such patients, improved diagnostic modalities, models of risk assessment, and an understanding of the various clinical situations in which infections occur have required that treatment approaches and options evolve. The development of broad-spectrum antibiotics with decreased toxicity has improved patient outcomes. Nevertheless, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis but, rather, should continue to incorporate standard infection control measures and demand careful handwashing by all health care professionals who come into contact with immunocompromised patients. Invasive fungal pathogens have increased and remain a major concern. Diagnostic and therapeutic modalities for fungal infections remain limited, but careful clinical investigation of new approaches will be needed to define the proper use of these probably expensive new therapeutic additions.

Original languageEnglish (US)
Pages (from-to)390-432
Number of pages43
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Issue number5
StatePublished - Sep 1 2004

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Fever and neutropenia clinical practice guidelines.'. Together they form a unique fingerprint.

Cite this